Repeated growth signals favor abnormal skin cell clones by crowding dividing neighbors

Epidermal growth factor receptor (EGFR)

A protein that receives growth signals. Activating it during repair is the intervention being questioned; receptor expression in a cancer is a different observation from the effects of temporarily stimulating it during wound repair.

Repair-limited stimulation and repeated pulses

Stimulation restricted to periods of repair, delivered on multiple occasions. These phrases do not specify a dose, treatment duration, or stopping rule in the supplied input.

Naturally photoaged skin

Human skin changed by accumulated sunlight exposure. It is the setting named by the question, rather than an experimentally engineered mouse wound.

Clone or cell family

Cells descended from a common starting cell. An abnormal clone carries changes of concern in this question, but the label alone does not establish that the cells are cancerous.

Mosaic

Tissue containing cell groups with different genetic makeups. Here, the distinction is between naturally occurring human variation and an experimentally engineered mixture in mice.

RAS and non-RAS

RAS names a group of genes used to distinguish the engineered mouse clones from other genetically altered clones. Non-RAS is a broad grouping of other changes, not one defined cell type; the supplied material does not identify the individual changes at issue.

Normal-cell competition

The proposed process in which normal cells limit the persistence or expansion of abnormal cell families. Its protective role in the stated mouse setting is a premise of the question, not a finding established by the supplied sources.

Selection, enrichment, and renewal advantage

Selection means that some cell families are favored over others; enrichment means that their relative representation increases. A renewal advantage is an advantage in replenishing cells, and the question asks whether such an advantage ends with repair or leaves cumulative changes.

RL-1

A label attached to the engineered mouse work in the gap description. The supplied material does not explain what the label denotes.

Cutaneous squamous-cell carcinoma

A type of skin cancer examined in both supplied sources. Findings in an existing cancer do not directly establish what happens during repair of naturally sun-aged skin.

Metastasis

The spread of cancer to other sites. S2's quoted suggestion concerns this outcome, rather than abnormal cell enrichment following repeated wound repair.

p63 and p73

Named regulators of gene activity studied in S5. The supplied quote identifies their joint regulation of several molecules that activate EGFR.

EGFR ligands

Molecules that bind to EGFR and provide signals through it. S5 discusses multiple such molecules, so the term names a class rather than a single substance.

Feed-forward signaling module

A connected set of regulatory steps that reinforces a downstream signal. S5 reports that the module involving p63, p73, and EGFR ligands amplifies signals promoting cell multiplication.

Preprint

A research manuscript shared before formal journal publication. S5 is identified as a preprint; the supplied input does not establish its peer-review status.

RL-1 engineered RAS-mosaic mouse wounds show protective normal-cell competition under repair-limited EGFR stimulation.

The assumption concerns experimentally altered mouse wounds containing a mixture of cells, including cells with changes in RAS genes, and a treatment that activates a growth-signal receptor only during repair. It claims that normal cells compete in a way that restrains abnormal cell families in this setting. If established, this would provide the mouse finding whose persistence in genetically varied, sun-aged human skin is being questioned.

Neither supplied source establishes the claimed RL-1 mouse result or protective normal-cell competition. S2 concerns receptor expression in an existing skin cancer, and S5 concerns a growth-signaling mechanism in skin cancer. The supplied search results therefore do not establish this premise; that does not show that the premise is false.S2S5

The same question asked without the part nothing read establishes:

• Does repeated EGFR stimulation limited to repair restrain or persistently enrich non-RAS abnormal cell families in naturally sun-aged human skin after wounds close and stimulation stops?
• Does normal wound closure after repeated repair-limited EGFR stimulation coincide with lasting changes in the relative abundance of abnormal cell families in naturally sun-aged human skin?

• Abnormal cell families remain restrained Under the proposed competition mechanism, repair stimulation would help normal cells limit abnormal cell families without giving those abnormal families a lasting advantage. Repeated closure would then be compatible with continued restraint after stimulation stops, although unchanged cancer risk would remain a separate requirement.
• Non-RAS abnormal cell families become persistently enriched Repeated repair stimulation would favor some cell families carrying changes outside the RAS group, and their increased representation would remain after the treatment ends. Normal wound closure and complete treatment cessation would therefore be insufficient evidence that the treatment's effects on cellular composition had ended.

The proposed benefit depends on stimulation helping repair while any advantage in cell renewal ends when each repair finishes. If abnormal cell families retain a relative advantage, repeated repairs could change the skin's cellular composition even when every wound closes normally. Wound closure would then fail to capture the persistent change that the question seeks to detect. Conversely, continued restraint would support the proposed protective effect, although restraint alone would not establish that cancer risk remains unchanged.